Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with InnoCare Pharma-B (09606) being included in the Hang Seng Composite Index, effective after market close on September 5, 2023, and effective from September 8, 2023 [1] - According to Huatai Securities research, InnoCare Pharma-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria including market capitalization, liquidity, and listing time [1] - InnoCare Pharma announced that its key product DB-1310, a targeted antibody-drug conjugate (ADC) for human epidermal growth factor receptor 3 (HER3), has received Fast Track designation from the U.S. FDA for treating adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have disease progression after treatment with EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy [1] Group 2 - DB-1310 is a next-generation ADC product targeting HER3 developed using the company's proprietary DITAC technology platform [2] - In June 2025, InnoCare Pharma presented the initial results of the Phase I/IIa clinical study (NCT05785741) of DB-1310 at the American Society of Clinical Oncology (ASCO) annual meeting, showing encouraging efficacy and manageable safety in patients with advanced solid tumors who had failed standard treatments [2]
映恩生物-B(09606)获纳入恒生综合指数 有望成为港股通标的